ArticleNature2023
Tracking early lung cancer metastatic dissemination in TRACERx using ctDNA.
Registry-linked trialOpen access · hybridAbstract read
In one paragraph
Article in Nature, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT05236114 (TEMPUS GEMINI NSCLC STUDY), which is not on this map. Cited by 245 papers, 2 of them syntheses that pooled it.
0numbers the graph read from it
0cells of the map it votes in
245citing papers in PubMed, 2 pooled it
75.8field-weighted citation impact, top 1% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
TEMPUS GEMINI NSCLC STUDY: A Longitudinal Multi-Omic Biomarker Profiling Study of Patients With Non-Small Cell Lung Cancer (NSCLC)
Who cites it
245 citing papers in PubMed, 2 syntheses or guidelines pooled it, 313 citations in OpenAlex.
- Clinical Utility of Circulating Tumour DNA (ctDNA) Analysis for Assessing Completeness of Primary Lesion Resection and Disease Stage in Patients with Melanoma: A Systematic Review.Medicina (Kaunas, Lithuania) · 2026Pooled it
- Predictive Effectiveness of Circulating Tumor DNA in Recurrent Early-Stage Non-Small Cell Lung Cancer: An Updated Meta-Analysis.JCO precision oncology · 2025Pooled it
- Trial
- Clinical utility of molecular residual disease detection in early-stage resected EGFR-mutated non-small cell lung cancer.Nature communications · 2026Trial
- Evaluation of Biomarkers for Sacituzumab Govitecan in Metastatic Non-Small Cell Lung Cancer: Insights From the EVOKE-01 Study.Cancer research communications · 2026Trial
- Monitoring treatment response using an ultra-sensitive ctDNA assay in advanced esophagogastric cancer patients.Scientific reports · 2026Trial
- Minimal Residual Disease Enhances Prognostic Stratification beyond Pathologic Response in Resectable Non-Small Cell Lung Cancer.Clinical cancer research : an official journal of the American Association for Cancer Research · 2026Trial
- Tumor-Informed ctDNA in Guiding First-Line Immunochemotherapy in Advanced Non-Small Cell Lung Cancers.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2025Trial
- Circulating tumor DNA monitoring and blood tumor mutational burden in patients with metastatic solid tumors treated with atezolizumab.Molecular oncology · 2025Trial
- Trial
- Perioperative nivolumab and chemotherapy in locally advanced squamous cell carcinoma of the oesophagus: a randomized multicentre phase 2 study with circulating tumor DNA dynamics monitoring.Molecular cancer · 2025Trial
- [Standard-of-care systemic therapy with or without SBRT in patients with oligoprogressive breast cancer or NSCLC (CURB oligoprogression): an open-label, randomised, controlled, phase 2 study].Strahlentherapie und Onkologie : Organ der Deutschen Rontgengesellschaft ... [et al] · 2024Trial
- Concordance of tumor-informed and tumor-agnostic ctDNA assays for treatment response monitoring in advanced solid tumors.The journal of liquid biopsy · 2026Article
- A multimodal AI biomarker PATH-ORACLE improves prediction of recurrence in stage I lung adenocarcinoma.Immuno-oncology technology · 2026Article
- Value and research advances of ctDNA in perioperative therapy for non-small cell lung cancer.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2026Review
- Assessment of MRD and Longitudinal Monitoring of Post-Surgery Biliary Tract Cancer With a Customized ctDNA Panel.Cancer science · 2026Article
- Mechanisms of systemic immune modulation in tumor development: Interactions across lymph nodes, bone marrow, and blood.Cancer metastasis reviews · 2026Review
- Review
- Clinical metastatic cancer from initiation to colonization: emerging challenges and breakthroughs.Oncogene · 2026Review
- Genomic instability, postoperative recurrence and therapeutic vulnerabilities in resectable non‑small cell lung cancer (Review).Oncology reports · 2026Review
185 more citing papers are in PubMed but not listed here.
Corrections and comments
- Commented on by
Authors and funding
55 authors at 20 institutions in 9 countries.
Christopher Abbosh *Cancer Research UK Lung Cancer Centre of Excellence, University College London Cancer Institute, London, UK. c.abbosh@ucl.ac.uk.ORCID http://orcid.org/0000-0002-8983-1382
Alexander M Frankell *Cancer Research UK Lung Cancer Centre of Excellence, University College London Cancer Institute, London, UK.ORCID http://orcid.org/0000-0002-0341-7878
Thomas Harrison *Invitae, San Francisco, CA, USA.
Judit Kisistok *Department of Molecular Medicine, Aarhus University Hospital, Aarhus, Denmark.
Aaron Garnett *Invitae, San Francisco, CA, USA.
Laura JohnsonInvitae, San Francisco, CA, USA.
Selvaraju VeeriahCancer Research UK Lung Cancer Centre of Excellence, University College London Cancer Institute, London, UK.
Mike MoreauInvitae, San Francisco, CA, USA.
Adrian CheshInvitae, San Francisco, CA, USA.
Tafadzwa L ChaunzwaArtificial Intelligence in Medicine (AIM) Program, Mass General Brigham, Harvard Medical School, Boston, MA, USA.
Jakob WeissArtificial Intelligence in Medicine (AIM) Program, Mass General Brigham, Harvard Medical School, Boston, MA, USA.
Morgan R SchroederInvitae, San Francisco, CA, USA.
Sophia WardCancer Research UK Lung Cancer Centre of Excellence, University College London Cancer Institute, London, UK.ORCID http://orcid.org/0000-0002-6777-5279
Kristiana GrigoriadisCancer Research UK Lung Cancer Centre of Excellence, University College London Cancer Institute, London, UK.ORCID http://orcid.org/0000-0002-8435-0176
Aamir ShahpurwallaInvitae, San Francisco, CA, USA.
Kevin LitchfieldCancer Research UK Lung Cancer Centre of Excellence, University College London Cancer Institute, London, UK.
Clare PuttickCancer Research UK Lung Cancer Centre of Excellence, University College London Cancer Institute, London, UK.
Dhruva BiswasCancer Research UK Lung Cancer Centre of Excellence, University College London Cancer Institute, London, UK.ORCID http://orcid.org/0000-0001-9141-5188
Takahiro KarasakiCancer Research UK Lung Cancer Centre of Excellence, University College London Cancer Institute, London, UK.ORCID http://orcid.org/0000-0001-6863-2360
James R M BlackCancer Research UK Lung Cancer Centre of Excellence, University College London Cancer Institute, London, UK.
Carlos Martínez-RuizCancer Research UK Lung Cancer Centre of Excellence, University College London Cancer Institute, London, UK.ORCID http://orcid.org/0000-0002-4817-0565
Maise Al BakirCancer Research UK Lung Cancer Centre of Excellence, University College London Cancer Institute, London, UK.ORCID http://orcid.org/0000-0002-0846-8332
Oriol PichCancer Evolution and Genome Instability Laboratory, The Francis Crick Institute, London, UK.ORCID http://orcid.org/0000-0002-1956-1882
Thomas B K WatkinsCancer Evolution and Genome Instability Laboratory, The Francis Crick Institute, London, UK.
Emilia L LimCancer Research UK Lung Cancer Centre of Excellence, University College London Cancer Institute, London, UK.
Ariana HuebnerCancer Research UK Lung Cancer Centre of Excellence, University College London Cancer Institute, London, UK.ORCID http://orcid.org/0000-0001-8009-4999
David A MooreCancer Research UK Lung Cancer Centre of Excellence, University College London Cancer Institute, London, UK.ORCID http://orcid.org/0000-0002-6296-1312
Nadia Godin-HeymannAstraZeneca, Cambridge, UK.ORCID http://orcid.org/0000-0003-3260-0302
Anne L'HernaultAstraZeneca, Cambridge, UK.
Hannah ByeAstraZeneca, Cambridge, UK.
Aaron OdellInvitae, San Francisco, CA, USA.
Paula KalavakurInvitae, San Francisco, CA, USA.
Fabio GomesThe Christie NHS Foundation Trust, Manchester, UK.
Akshay J PatelUniversity Hospital Birmingham NHS Foundation Trust, Birmingham, UK.
Elizabeth ManzanoCancer Research UK Lung Cancer Centre of Excellence, University College London Cancer Institute, London, UK.
Crispin T HileyCancer Research UK Lung Cancer Centre of Excellence, University College London Cancer Institute, London, UK.
Nicolas CareyCancer Research Centre, University of Leicester, Leicester, UK.ORCID http://orcid.org/0000-0002-2660-9178
Joan RileyCancer Research Centre, University of Leicester, Leicester, UK.
Daniel E CookCancer Evolution and Genome Instability Laboratory, The Francis Crick Institute, London, UK.ORCID http://orcid.org/0000-0003-3347-562X
Darren HodgsonAstraZeneca, Cambridge, UK.
Daniel StetsonAstraZeneca, Waltham, MA, USA.
J Carl BarrettAstraZeneca, Waltham, MA, USA.
Roderik M KortleverDepartment of Biochemistry, University of Cambridge, Cambridge, UK.ORCID http://orcid.org/0000-0001-5558-2851
Gerard I EvanDepartment of Biochemistry, University of Cambridge, Cambridge, UK.ORCID http://orcid.org/0000-0003-0412-1216
Allan HackshawCancer Research UK & UCL Cancer Trials Centre, London, UK.ORCID http://orcid.org/0000-0002-5570-5070
Robert D DaberInvitae, San Francisco, CA, USA.
Jacqui A ShawCancer Research Centre, University of Leicester, Leicester, UK.ORCID http://orcid.org/0000-0003-4227-503X
Hugo J W L AertsArtificial Intelligence in Medicine (AIM) Program, Mass General Brigham, Harvard Medical School, Boston, MA, USA.ORCID http://orcid.org/0000-0002-2122-2003
Abel LiconInvitae, San Francisco, CA, USA.
Josh StahlInvitae, San Francisco, CA, USA.
Mariam Jamal-HanjaniCancer Research UK Lung Cancer Centre of Excellence, University College London Cancer Institute, London, UK.ORCID http://orcid.org/0000-0003-1212-1259
TRACERx Consortium
Nicolai J BirkbakCancer Research UK Lung Cancer Centre of Excellence, University College London Cancer Institute, London, UK.ORCID http://orcid.org/0000-0003-1613-9587
Nicholas McGranahanCancer Research UK Lung Cancer Centre of Excellence, University College London Cancer Institute, London, UK. nicholas.mcgranahan.10@ucl.ac.uk.ORCID http://orcid.org/0000-0001-9537-4045
Charles SwantonCancer Research UK Lung Cancer Centre of Excellence, University College London Cancer Institute, London, UK. Charles.Swanton@crick.ac.uk.ORCID http://orcid.org/0000-0002-4299-3018
The Francis Crick Institute · GBCancer Research UK · GBLondon Cancer · GBRoyal London Hospital · GBGuy's and St Thomas' NHS Foundation Trust · GBInvitae (United States) · USManchester University NHS Foundation Trust · GBUniversity Hospitals of Leicester NHS Trust · GBUniversity of Leicester · GBUniversity Hospitals Birmingham NHS Foundation Trust · GBUniversity Hospital Southampton NHS Foundation Trust · GBGolden Jubilee National Hospital · GBUniversity College London · GBAberdeen Royal Infirmary · GBAstraZeneca (United Kingdom) · GBInstitute of Cancer Research · GBUniversity College Hospital · GBUniversity of Manchester · GBAarhus University · DKBrigham and Women's Hospital · US
Funding
The Boston Lung Cancer Survival CohortU01CA209414 · NCI · HARVARD UNIVERSITY D/B/A HARVARD SCHOOL OF PUBLIC HEALTH · PI David C Christiani · 2017 to 2026
$12.2MQuantitative Radiomics System Decoding the Tumor PhenotypeU24CA194354 · NCI · DANA-FARBER CANCER INST · PI AERTS, HUGO, QUACKENBUSH, JOHN · 2015 to 2019
$3.5MGenotype and Imaging Phenotype Biomarkers in Lung CancerU01CA190234 · NCI · DANA-FARBER CANCER INST · PI AERTS, HUGO, QUACKENBUSH, JOHN · 2015 to 2019
$3.3MCancer Research UK 17786Cancer Research UK 21999Cancer Research UK 24956Cancer Research UK 25349Cancer Research UK 29569Cancer Research UK 30025Cancer Research UK A17786Cancer Research UK CC2041Cancer Research UK CTRNBC-2022/100001Medical Research Council MR/V033077/1Medical Research Council MR/W025051/1NCI NIH HHS U01 CA190234NCI NIH HHS U01 CA209414NCI NIH HHS U24 CA194354Wellcome Trust CC2041
Abstract
Circulating tumour DNA (ctDNA) can be used to detect and profile residual tumour cells persisting after curative intent therapy
Indexed as
Biomarkers, TumorCarcinoma, Non-Small-Cell LungCirculating Tumor DNALung NeoplasmsMutationNeoplasm MetastasisSmall Cell Lung CarcinomaCohort StudiesHumansLiquid BiopsyNeoplasm Recurrence, LocalPhylogenyBiomarkers, TumorCirculating Tumor DNA
Identifiers
What OpenQuestion holds
Textmetadata
LicenceCC BY
Read underepoch 390
Registered trials
NCT05236114ClinicalTrials.gov
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.